Sodium adenosine triphosphate - description of the drug, instructions for use, reviews. Sodium adenosine triphosphate-darnitsa Interactions with other drugs
solution for injections 10mg/ml: 1 ml amp.10 pcs.Reg. No: 3510/98/05/11/11 dated 02/22/2011 - Expired
Excipients: sodium hydroxide 2 M, water for injection.
1 ml - ampoules (10) - boxes.
1 ml - ampoules (5) - blisters (2) - packs.
Description medicinal product SODIUM ADENOSINE TRIFOSPHATE-DARNITSA created in 2015 on the basis of instructions posted on the official website of the Ministry of Health of the Republic of Belarus. Date of update: 05/20/2015
Adenosine triphosphate (ATP) is a natural macroergic compound. It is synthesized in almost all tissues of the body by oxidative phosphorylation and in the process of carbohydrate breakdown. Most of all, it is synthesized in muscle tissue, where the energy contained in ATP molecules is used during muscle contraction. The energy released during the breakdown of ATP is used in the processes of synthesis, in particular protein, urea.
In the nervous system, ATP molecules act as a neurotransmitter, transmitting a signal in purinergic synapses. At the same time, ATP accompanies acetylcholine and noradrenergic mediation.
When administered systemically, sodium adenosine triphosphate-Darnitsa exhibits a metabolic, antiarrhythmic effect, improves cerebral and coronary circulation. The antiarrhythmic effect is associated with the suppression of the automatism of the sinus node and the conduction of impulses along the Purkinje fibers.
Partially blocks calcium channels and facilitates the transmembrane movement of potassium ions.
It is not possible to track the kinetics of a parenterally administered ATP preparation due to the high voltage of various reactions that occur with the participation of one's own ATP. At the same time, it is known that sodium adenosine triphosphate rapidly decomposes at the injection site into adenosine and phosphate residues, which are subsequently used to synthesize new ATP molecules.
Sodium adenosine triphosphate-Darnitsa is administered intramuscularly or intravenously.
For the treatment of muscular dystrophies, peripheral circulatory disorders in the first 2-3 days, 1 ml intramuscularly 1 time / day is prescribed, in the following days - 1 ml 2 times / day or immediately 2 ml 1 time / day. The course of treatment is 30-40 days. If necessary, the course is repeated after 1-2 months.
In case of hereditary pigmentary retinal degeneration, 5 ml intramuscularly is administered 2 times / day, with an interval of 6-8 hours, daily for 15 days. If necessary, courses can be repeated at intervals of 8-12 months.
To stop supraventricular tachyarrhythmias, 1-2 ml is injected intravenously over 5-10 seconds (the effect is observed after 20-40 seconds). If necessary, repeat the same dose after 2-3 minutes.
From the side of the central nervous system: headache, dizziness, short-term loss of consciousness, a feeling of constriction in the head, phobias.
From the side of the organ of vision: blurred vision.
From the gastrointestinal tract: nausea, metallic taste in the mouth, increased motility of the gastrointestinal tract (with a / in the introduction).
From the side of cardio-vascular system: palpitations, discomfort in chest, tachycardia or bradycardia, arterial hypotension, arrhythmia, impaired AV conduction (atrioventricular block), asystole.
From the musculoskeletal system: pain in the arms, back, neck.
From the urinary system: increased diuresis.
From the side respiratory system: shortness of breath, bronchospasm.
skin changes and subcutaneous tissue: flushing of the face, itching, skin rash.
Injection site disorders: tingling sensation.
Allergic reactions: hypersensitivity reactions, allergic dermatitis, urticaria, anaphylactic shock.
General disorders: increased sweating, hyperthermia, sensation of heat.
In / in the introduction of the drug, as a rule, it is necessary to carry out in a hospital, under medical supervision, with monitoring of heart function, slowly, after which it is desirable to measure blood pressure.
Children
There is no experience of using the drug in children, so the drug is contraindicated in this age group.
Use with caution in severe bradycardia, sick sinus syndrome, first degree AV block, and a tendency to arterial hypotension.
The drug should not be administered in large doses simultaneously with cardiac glycosides.
The ability to influence the reaction rate when driving vehicles or working with other mechanisms
During treatment, you should refrain from driving vehicles or working with other mechanisms that require increased attention.
Symptoms: dizziness, arterial hypotension, short-term loss of consciousness, arrhythmia, atrioventricular block II and III degree, asystole, bronchospasm, ventricular disturbances, sinus bradycardia and tachycardia. It is also possible to develop allergic reactions.
Treatment. The introduction of the drug is immediately stopped and cardiotonic drugs are prescribed. Therapy is symptomatic. Competitive antagonists of adenosine are xanthines (eufillin, theophylline).
When used together with dipyridamole, the effect of dipyridamole is enhanced, in particular the vasodilating effect.
There is some antagonism when the drug is used together with purine derivatives (caffeine and theophylline).
It should not be administered simultaneously with cardiac glycosides in large doses, as the risk of developing adverse reactions from the cardiovascular system. With simultaneous use with xanthinol nicotinate, the effect of sodium adenosine triphosphate is reduced.
Carbamazepine may enhance the effects of adenosine, leading to the development of blockade.
The drug should not be administered simultaneously with carbamazepine, dipyridamole, xanthines, antiarrhythmic drugs.
25.02.2012 9250
ATP (sodium adenosine triphosphate). Description, instruction.
Supraventricular paroxysmal tachycardia (paroxysm relief). Previously, the drug was used for the following indications (currently, due to low efficacy, the following indications are excluded): muscular dystrophy and atrophy, poliomyelitis, multiple sclerosis...
International name:
Triphosadenine (Triphosadenine)
Description of the active substance (INN):
Trifosadenine
Dosage form:
lyophilizate for preparation of solution for intravenous administration, solution for intravenous administration
Pharmachologic effect:
Metabolic agent, has a hypotensive and antiarrhythmic effect, dilates the coronary and cerebral arteries. It is a natural macroergic compound. It is formed in the body as a result of oxidative reactions and in the process of glycolytic breakdown of carbohydrates. Contained in many organs and tissues, but most of all - in the skeletal muscles. Improves metabolism and energy supply of tissues. Splitting into ADP and inorganic phosphate, ATP releases a large number of energy used for muscle contraction, protein synthesis, urea, intermediate metabolic products, etc. In the future, decay products are included in ATP resynthesis. Under the influence of ATP, there is a decrease in blood pressure and relaxation of smooth muscles, the conduction of nerve impulses in autonomic ganglia and transfer of excitation from n.vagus to the heart, myocardial contractility increases. ATP inhibits the automatism of the sinoatrial node and Purkinje fibers (blockade of Ca2+ channels and increased permeability to K+).
Indications:
Supraventricular paroxysmal tachycardia (paroxysm relief). Previously, the drug was used for the following indications (at present, due to low efficacy, the following indications are excluded): muscular dystrophy and atrophy, poliomyelitis, multiple sclerosis, coronary insufficiency, postinfarction cardiomyodystrophy, acute and chronic cardiovascular insufficiency, obliterating diseases of the arteries - "intermittent lameness, Raynaud's disease, thromboangiitis obliterans (Buerger's disease), hereditary pigmentary degeneration retina, weakness of labor activity.
Contraindications:
Hypersensitivity, acute myocardial infarction, arterial hypotension, inflammatory diseases lungs.
Side effects:
Allergic reactions (itching, skin hyperemia). With the / m administration - headache, tachycardia, increased diuresis, hyperuricemia; with intravenous - nausea, flushing of the skin of the face, headache, weakness.
Dosage and administration:
In / m, in / in or in / a. In the first days of treatment - in / m, 10 mg (1 ml of a 1% solution) 1 time per day, then at the same dose 2 times a day or 20 mg 1 time per day. The course of treatment - 30-40 injections, repeated course - after 1-2 months. For the relief of supraventricular arrhythmias - in / in, 10-20 mg, for 5-6 seconds (the effect occurs after 30-40 seconds), if necessary, repeated administration is possible after 2-3 minutes.
Special instructions:
Do not administer large doses simultaneously with cardiac glycosides.
Interaction:
Cardiac glycosides increase the risk of side effects (including arrhythmogenic effects).
Colorless or slightly yellowish clear liquid
Compound
1 ml sodium adenosine triphosphate 0.01 g
Excipients: water for ¢ injections, sodium hydroxide solution diluted R.
Release form
Injection.
Pharmacological group"type="checkbox">
Pharmacological group
Other cardiac drugs. Adenosine ATC code C01E B10.
Pharmacological properties"type="checkbox">
Pharmacological properties
Pharmacological. ATP is involved in many metabolic processes in the body. Interacting with the contractile proteins actomyosin, it breaks down into adenosine diphosphoric acid (ADP) and inorganic phosphate, releasing energy that is used by muscles to implement mechanical functions. Energy is also needed for synthetic processes (protein synthesis, urea).
Under the influence of sodium adenosine triphosphate, smooth m¢ muscles relax, the conduction of nerve impulses in the autonomic nodes and the transmission of excitation are facilitated. vagus nerve on the heart. In the process of metabolism, ATP inhibits the automatism of the sinoatrial node and Purkinje fibers. The antiarrhythmic effect is realized due to the formation of adenosine and partially blockade of calcium channels.
Pharmacokinetics. Interacting with the contractile proteins actomyosin, ATP breaks down into adenosine diphosphoric acid (ADP) and inorganic phosphate, releasing energy that is used by m ¢ muscles to perform mechanical functions, as well as for synthesis processes (protein synthesis, urea). Antiarrhythmic effect after the introduction occurs in 20 - 40 seconds.
Indications
Complex therapy m ¢ muscular dystrophy and atrophy, for the treatment of paroxysms of ventricular tachycardia. In combination with other drugs for spasms of peripheral vessels (intermittent claudication, Raynaud's disease, thromboangiitis obliterans), sometimes - to stimulate labor; peripheral, mixed and central forms hereditary retinitis pigmentosa.
Dosage and administration
Sodium adenosine triphosphate is usually administered intramuscularly ¢ intramuscularly. For the treatment of m ¢ muscular dystrophies, peripheral circulatory disorders, in the first 2-3 days, 1 ml of 1% solution 1 time per day, in the following days - 1 ml of 1% solution 2 times a day or immediately 2 ml of 1% solution 1 once a day. The course of treatment is 30 - 40 days. If necessary, the course is repeated after 1 - 2 months. In case of hereditary retinal pigment degeneration, 5 ml of a 1% solution is administered 2 times a day with an interval of 6-8 hours daily for 15 days. If necessary, courses can be repeated at intervals of 8 - 12 months. To stop supraventricular tachyarrhythmias, 1-2 ml of a 1% solution is injected intravenously over 3-5 seconds (the effect is observed after 20-40 seconds). If necessary, re-introduce at the same dose after 2 to 3 minutes.
Side effect"type="checkbox">
Side effect
With the ¢ m administration of sodium adenosine triphosphate, headache, tachycardia, brodycardia, impaired AV conduction, increased diuresis are possible, with intravenous administration - nausea, flushing of the face, headache. Possible allergic reactions. When expressed side effects the drug is cancelled.
With intravenous administration, arrhythmias may develop, including AV blockade, asystole, hypotension, and shortness of breath. Therapy of conditions is symptomatic.
Contraindications
The use of Sodium adenosine triphosphate is contraindicated in acute myocardial infarction, individual hypersensitivity, AV blockade II - III centuries. Childhood up to 14 years old.
Trifosadenine (sodium adenosine triphosphate) (triphosadenine)
Composition and form of release of the drug
Solution for intravenous administration colorless or slightly yellowish, transparent.
* disodium adenosine triphosphate dihydrate in terms of adenosine triphosphoric acid.
Excipients: anhydrous sodium carbonate - 4.4 mg, - 8 mg, disodium edetate dihydrate - 0.2 mg, propylene glycol - 0.1 mg, water for injection - up to 1 ml.
1 ml - ampoules (5) - packs of cardboard.
1 ml - ampoules (10) - packs of cardboard.
1 ml - ampoules (5) - blister packs made of polyvinyl chloride film (1) - cardboard packs.
1 ml - ampoules (5) - blister packs made of polyvinyl chloride film (2) - cardboard packs.
1 ml - ampoules (5) - blister packs made of polyvinyl chloride film (4) - cardboard packs (for hospitals).
1 ml - ampoules (5) - blister packs made of polyvinyl chloride film (5) - cardboard packs (for hospitals).
1 ml - ampoules (5) - blister packs made of polyvinyl chloride film (10) - cardboard packs (for hospitals).
1 ml - ampoules (5) - blister packs made of polyvinyl chloride film (50) - cardboard packs (for hospitals).
1 ml - ampoules (5) - blister packs made of polyvinyl chloride film (100) - cardboard packs (for hospitals).
pharmachologic effect
Means that improves metabolism and energy supply of tissues. ATP is a natural component of body tissues - it is involved in many metabolic processes. When ATP breaks down into ADP and inorganic phosphate, the energy necessary for muscle contraction and various biochemical processes is released. ATP is involved in the transmission of excitation in adrenergic and cholinergic synapses, facilitates the transfer of excitation from the vagus nerve to the heart. Apparently, ATP is one of the mediators that excite adenosine receptors. Enhances cerebral and coronary circulation, promotes an increase in peripheral circulation.
Trifosadenine is a derivative of adenosine. Adenosine is an agonist of purinergic receptors, the activation of which leads to inhibition of the depolarization of the processes of conducting electrical impulses in the sinus and AV nodes. This effect underlies the antiarrhythmic action of triphosadenine in supraventricular tachycardia. Acts briefly for a few seconds.
Pharmacokinetics
After parenteral administration, it penetrates into the cells of organs, where it is cleaved into adenosine and inorganic phosphate with the release of energy. In the future, the decay products are included in the resynthesis of ATP.
Indications
Muscular dystrophy and atony, poliomyelitis,; retinitis pigmentosa; peripheral vascular disease (intermittent claudication, Raynaud's disease, thromboangiitis obliterans); relief of paroxysms of supraventricular tachycardia, ischemic heart disease; weakness of labor activity.
Contraindications
Acute, arterial hypotension, inflammatory diseases of the lungs, hypersensitivity to triphosadenine.
Dosage form: solution for intravenous administration Compound:1 ml of solution contains:
active substance : sodium adenosine triphosphate disubstituted 10.00 mg;
Excipients:
sodium hydroxide solution 2M to pH 7.0 - 7.3, water for injection up to 1 ml. Description: Clear, colorless or slightly yellowish liquid. Pharmacotherapeutic group:metabolic agent ATX:C.01.E.B Other drugs for the treatment of heart disease
Pharmacodynamics:Metabolic agent, has a hypotensive and antiarrhythmic effect, dilates the coronary and cerebral arteries. It is a natural macroergic compound. It is formed in the body as a result of oxidative reactions and in the process of glycolytic breakdown of carbohydrates. Contained in many organs and tissues, but most of all - in the skeletal muscles.
Improves metabolism and energy supply of tissues. Splitting into ADP and inorganic phosphate, it releases a large amount of energy used for muscle contraction, protein synthesis, urea, intermediate metabolic products, etc. Later, the decay products are included in ATP resynthesis. Under the influence of triphosadenine, there is a decrease blood pressure and relaxation of smooth muscles, the conduction of nerve impulses in the autonomic ganglia and the transfer of excitation from n.vagus to the heart improve, myocardial contractility increases. suppresses the automatism of the sinus-atrial node and Purkinje fibers (blockade of Ca 2+ channels and an increase in permeability to K +).
It is not possible to track the kinetics of a parenterally administered ATP preparation due to the high voltage of various reactions that occur with the participation of one's own ATP. However, it is known that sodium adenosine triphosphatequickly decomposes at the injection site into phosphate residues, which are subsequently used to synthesize new ATP molecules. Indications:Relief of paroxysms of supraventricular tachycardia (excluding flicker and / or atrial flutter).
Contraindications:Hypersensitivity to the drug, acute myocardial infarction, severe arterial hypotension, severe bradycardia, sick sinus syndrome, atrioventricular block II-III degree (except for patients with an artificial pacemaker), chronic obstructive pulmonary disease, bronchial asthma, long QT syndrome, acute and chronic heart failure in the stage of decompensation, pregnancy, lactation, age up to 18 years.
Children
There is no experience of using the drug in children (under 18 years of age).
Carefully:Bradycardia, atrioventricular block I degree, bundle branch block, atrial fibrillation and flutter, arterial hypotension, coronary heart disease, hypovolemia, pericarditis, valvular stenosis, left-to-right arteriovenous shunt, insufficiency cerebral circulation, conditions after heart transplantation (less than 1 year).
Pregnancy and lactation:Information regarding the use of the drug during pregnancy and breastfeeding missing.
Dosage and administration:The drug is administered intravenously quickly into the central or large peripheral vein, 3 mg for 2 seconds under the control of ECG and blood pressure; if necessary, after 1-2 minutes, 6 mg is re-introduced, after 1-2 minutes - 12 mg.
Treatment is stopped with the development of AV blockade at any of the stages of administration.
Side effects:The incidence of side effects is classified according to the recommendations of the World Health Organization: very often - more than 1/10; often - more than 1/100 and less than 1/10; infrequently - more than 1/1000 and less than 1/100; rarely - more than 1/10000 and less than 1/1000; very rarely - more than 1/10000; frequency not established (frequency cannot be estimated from available data).
From the side of the cardiovascular system: very often - flushing of the skin of the face, a feeling of discomfort in the chest (feeling of "squeezing", pain), bradycardia, sinus node arrest, atrioventricular blockade, various atrial and ventricular extrasystoles, ventricular tachycardia; infrequently - sinus tachycardia, palpitations; very rarely - atrial fibrillation, severe bradycardia not stopped by the introduction of atropine and requiring the setting of an artificial pacemaker, ventricular fibrillation, tachycardia of the "pirouette" type; the frequency has not been established - a pronounced decrease in blood pressure, asystole / cardiac arrest, sometimes fatal (in patients ischemic disease hearts).From the side of the central nervous system : often - headache, dizziness, various phobias; infrequently - a feeling of "pressure" in the head; very rarely - transientraise intracranial pressure; frequency not established - loss of consciousness / fainting, convulsions.
From the organ of vision: infrequently - visual impairment.
From the respiratory system: very often - shortness of breath; infrequently - rapid breathing; very rarely - bronchospasm; frequency not established - respiratory failure, apnea / respiratory arrest.
From the gastrointestinal tract: often - nausea; infrequently - a metallic taste in the mouth; frequency not established - vomiting.
Other: infrequently - increased sweating, weakness; very rarely - reactions at the injection site (tingling sensation).
Overdose:Symptoms: may be manifested by dizziness, arterial hypotension, short-term loss of consciousness, arrhythmia.
Treatment : the introduction of the drug is immediately stopped (due to the short half-life side effects pass quickly). If necessary, it is possible to introduce xanthines ( , ), which are competitive antagonists of triphosadenine and reduce its effect.
Interaction:Dipyridamole - enhances the action of triphosadenine, in some cases up to asystole, so the simultaneous administration of drugs is not recommended. If it is necessary to administer triphosadenine, it is necessary to stop treatment with dipyridamole 24 hours before the administration of triphosadenine or reduce its dose.
Purine derivatives (coffeine and) and xanthinol nicotinate - and other xanthines are competitive antagonists of triphosadenine, their use should be avoided within 24 hours before the administration of triphosadenine.
Xanthine-containing products (including tea, coffee, chocolate) should not be consumed 12 hours before the administration of the drug.
Carbamazepine may increase the inhibitory effect of triphosadenine on atrioventricular conduction, which can lead to complete atrioventricular block
You can not enter simultaneously with cardiac glycosides in large doses, as the risk of adverse reactions from the cardiovascular system increases.
Special instructions:The introduction of the drug, as a rule, should be carried out only intravenously under medical supervision, while monitoring heart function and blood pressure.
Due to the risk of arterial hypotension, the drug should be used with caution in patients with coronary heart disease, hypovolemia, pericarditis, valvular stenosis, left-to-right arteriovenous shunt, cerebrovascular insufficiency. Sodium adenosine triphosphate-Darnitsa should be used with caution in patients who have recently had a myocardial infarction, with severe chronic heart failure, a violation of the conduction system of the heart (atrioventricular blockade of the 1st degree, blockade of the bundle of His bundle) due to the possibility of their aggravation with the introduction of the drug. With the development of angina pectoris, severe bradycardia, arterial hypotension, respiratory failure or asystole/cardiac arrest, the drug should be discontinued. The drug can cause convulsions in predisposed patients (convulsions in history of various origins).
Previously, the drug was used for the following indications (at present, due to low efficacy, the following indications are excluded): muscular dystrophy and atrophy, poliomyelitis, multiple sclerosis, coronary insufficiency, postinfarction cardiomyodystrophy, acute and chronic cardiovascular insufficiency, obliterating diseases of the arteries - "intermittent " lameness, Raynaud's disease, thromboangiitis obliterans (Buerger's disease), hereditary pigmentary retinal degeneration, weakness of labor activity.
Influence on the ability to drive transport. cf. and fur.:The effect of the drug on the ability to drive vehicles and other mechanisms has not been studied. Release form / dosage:Solution for intravenous administration. Package:1 ml in an ampoule.
It is allowed to stick a label made of paper with a self-adhesive coating on the ampoule.
5 ampoules with a knife for opening ampoules or an ampoule scarifier in a blister pack (cassette).
Two blister packs with instructions for medical use in a pack.
By
10 ampoules with a knife for opening ampoules or an ampoule scarifier in a blister pack(cassette).By1 contourcell packaging with instructions for medical application in a pack. 10 ampoules with instructions for medical application, a knife for opening ampoules or an ampoule scarifierin a box with a corrugated liner. The box is pasted over with a label-package.When packing ampoules with a colored break ring
or breaking pointa knife for opening ampoules or an ampoule scarifier is not included. Storage conditions:Store in original packaging at temperatures between 2°C and 8°C.
Keep out of the reach of children.
Best before date:Do not use after the expiry date stated on the packaging.
Conditions for dispensing from pharmacies: On prescription Registration number: P N010635 Date of registration: 25.04.2012 / 25.04.2013 Expiration date: Perpetual Registration certificate holder:DARNITSA PHARMACEUTICAL FIRM, CJSC Ukraine Manufacturer: Information update date: 26.05.2018 Illustrated Instructions
